Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Myriad Genetics’ SEC disclosures can feel like parsing a clinical-trial protocol—dense tables on genetic test volumes, shifting reimbursement rates, and pages of R&D footnotes. If you have ever searched “Myriad Genetics SEC filings explained simply” or wondered how to spot insider confidence before a new assay launch, you know the challenge.
Stock Titan turns that complexity into clarity. Our AI instantly surfaces what matters in each document, from Myriad Genetics quarterly earnings report 10-Q filing to Myriad Genetics annual report 10-K simplified. You’ll get real-time alerts on Myriad Genetics Form 4 insider transactions, quick summaries of 8-K clinical-trial updates, and context for reimbursement disclosures—no scrolling through hundreds of pages.
Here’s how investors use the page:
- Track Myriad Genetics insider trading Form 4 transactions minutes after they hit EDGAR.
- Compare segment growth with AI-annotated MD&A sections in every 10-Q.
- Read the Myriad Genetics proxy statement executive compensation to see how management incentives align with test adoption goals.
- Dive into Myriad Genetics 8-K material events explained to understand FDA feedback or partnership announcements.
Whether you’re understanding Myriad Genetics SEC documents with AI for a quick investment decision or performing a deep Myriad Genetics earnings report filing analysis, our platform delivers:
- AI-powered plain-English summaries and keyword search across all filings
- Real-time updates the moment a new form is posted
- Comprehensive coverage—from 10-Ks and 10-Qs to insider Form 4 trades
- Expert commentary that links genetic-testing milestones to financial impact
Stop wading through technical disclosures. Access the complete story behind Myriad Genetics’ strategy, finances, and insider moves—clearly laid out in one place.
Scott J. Leffler, listed as Chief Financial Officer and reporting person for Myriad Genetics Inc. (MYGN), filed an "Exit" Form 4 stating he is no longer serving as CFO effective August 15, 2025. The Form 4, filed August 18, 2025, reports a disposition of 218,393 shares of Common Stock (transaction code D) and indicates the filer is no longer subject to Section 16 reporting. The filing was submitted on behalf of Mr. Leffler by Justin Hunter. No derivative transactions or additional compensation details are included in this Form 4.
Myriad Genetics (MYGN) announced a change in its finance leadership: Scott J. Leffler ceased serving as Chief Financial Officer effective August 15, 2025, and Ben R. Wheeler was appointed CFO effective August 16, 2025. Mr. Wheeler, a 13-year company veteran and CPA, previously held senior finance roles including SVP, Chief Financial Officer, Operations, and SVP, Finance and Treasury. His employment agreement sets an annual base salary of $490,000, an annual target cash bonus of 75% of base salary, standard benefit participation, and an initial equity award totaling 120,000 restricted stock units (60,000 time-based, 60,000 performance/time-based). Mr. Leffler will remain as a non-executive employee briefly to assist the transition.
Disciplined Growth Investors, Inc. reports beneficial ownership of 753,956 shares of Myriad Genetics common stock, representing 0.8% of the class. The filer states it has sole voting and dispositive power over these shares and that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer. The filing identifies Myriad Genetics' principal executive offices in Salt Lake City and provides the reporting person’s Minnesota address.
Barclays PLC reported beneficial ownership of 4,899,951 shares of Myriad Genetics common stock, equal to 5.31% of the class. The filing shows Barclays has sole voting and dispositive power over 4,762,680 shares and shared voting and dispositive power over 137,271 shares. The reporting person is classified as HC and the filing identifies related subsidiaries as Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
This document is a Schedule 13G disclosure and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence the control of the issuer.
FAQ
What is the current stock price of Myriad Genetics (MYGN)?
What is the market cap of Myriad Genetics (MYGN)?
